GenoMed, Inc. Announces Publication of Its Treatment to Delay Chronic Kidney Failure
ST. LOUIS, Sept. 10 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board GMED) ("the Company" or "GenoMed") a St. Louis, Missouri-based medical genomics biotechnology company, announced today that its novel treatment method for chronic kidney disease was published in the journal Diabetes Technology and Therapeutics.
Diabetes Technology and Therapeutics is a peer-reviewed, bimonthly journal which focuses on state-of-the-art treatments for diabetes. The article, entitled "From Pharmacogenomics to Improved Patient Outcomes: Angiotensin I- Converting Enzyme as an Example," by Dr. David W. Moskowitz, GenoMed's Chairman and Chief Medical Officer, appeared in the August/September issue, released today. Angiotensin I-converting enzyme's common abbreviation is ACE. The study describes the use of two currently available ACE inhibitors, quinapril and ramipril, in the successful treatment of four diseases: chronic kidney disease due to type 2 diabetes, chronic kidney disease due to high blood pressure, poor circulation due to high blood pressure, and emphysema. For the latter two diseases, only case reports were available.
Dr. David Moskowitz, GenoMed's Chairman, said, "I am delighted that Dr. David Klonoff, the Editor of Diabetes Technology and Therapeutics, and the journal's reviewers, have considered my observational clinical experience worthy of publication. I found that a higher dose of a specific ACE inhibitor, quinapril, was extremely effective in delaying chronic kidney disease due to diabetes or high blood pressure in both white and black men. In fact, if the treatment was started early enough in the course of the disease, kidney failure was reversed altogether, the first time this has ever been reported."
Dr. Moskowitz added, "This has immediate implications for the 60 million Americans with high blood pressure and the 20 million Americans with diabetes, as well as the primary care physicians who care for them. If the pilot data for emphysema can be replicated, then an additional 16 million Americans with emphysema could benefit from GenoMed's patented treatment methods. GenoMed is launching the Next Generation of Disease Management(TM) to commercialize these results."
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or fax,
+1-314-977-0042, or kfischer@genomedics.com
Web site: genomedics.com
. |
